BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.05 CNY | +0.23% |
|
-2.12% | -25.38% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -25.38% | 805M | - | ||
| +41.79% | 50.93B | B- | ||
| -0.56% | 42.12B | B | ||
| +49.62% | 42.05B | A | ||
| -7.20% | 29.18B | C | ||
| +12.59% | 26.02B | B- | ||
| -21.51% | 18.9B | B | ||
| +6.92% | 13.21B | B+ | ||
| +24.91% | 12.17B | B+ | ||
| +29.60% | 12.16B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- 688621 Stock
- Ratings Beijing Sun-Novo Pharmaceutical Research Co., Ltd.